Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Brain immune discoveries are directly leading to new drugs in clinical trials right now. Over the past year, researchers have identified multiple drug targets within the brain’s immune system—the microglial cells, inflammatory proteins, and immune pathways that protect or harm the brain—and these findings are moving rapidly toward therapies for diseases ranging from Alzheimer’s disease to glioblastoma. As of February 2026, a new drug target for anti-NMDAR encephalitis (commonly called “brain on fire”) was discovered using advanced imaging techniques called cryo-EM to study how autoantibodies bind to brain receptors, showing exactly what cells and proteins scientists need to target with new medications.
The shift is significant because for decades, researchers treated the brain’s immune system as a side effect to manage, not a therapeutic target to exploit. Now, 18% of Alzheimer’s disease drugs currently in Phase 3 clinical trials are specifically designed to modify immune biology—activating beneficial immune responses or dampening harmful inflammation. These aren’t theoretical concepts; they’re medicines being tested in patients right now, with results that could reshape how we treat not only Alzheimer’s but also ALS, depression, and other neurological conditions.
Table of Contents
- Why the Brain’s Immune System Is Becoming a Drug Development Hotspot
- Five Drug Candidates in Active Clinical Trials Targeting Brain Immunity
- From Cryo-EM Images to Clinical Drugs: The Anti-NMDAR Encephalitis Example
- Autoimmune Diseases and Neurodegeneration: A Surprising Connection Worth Treating
- The Blood-Brain Barrier: The Biggest Hurdle in Brain Immune Drug Development
- uPAR CAR T Cells and Engineered Immune Therapy for Glioblastoma
- The Future Landscape of Brain Immune-Targeted Drugs
- Conclusion
Why the Brain’s Immune System Is Becoming a Drug Development Hotspot
For years, neuroscience viewed the brain as an immune-privileged site—a place largely protected from the body’s immune system. But recent discoveries revealed that the brain has its own dedicated immune cells called microglia, along with immune-signaling molecules that deeply influence whether neurons survive or die. When these immune processes go wrong—becoming either too aggressive or too suppressed—neurodegeneration accelerates. This discovery has opened an entirely new frontier in drug development because the brain’s immune system represents dozens of potential drug targets that were essentially invisible to pharmaceutical research a decade ago.
The appeal is clear: unlike some neurodegenerative diseases where the underlying cause remains mysterious, researchers can now point to specific immune molecules driving damage. For example, elevated levels of IL-1β (an inflammatory protein) correlate with faster cognitive decline in Alzheimer’s patients, making IL-1β-blocking drugs like canakinumab direct candidates for clinical testing. Similarly, TREM2 (a receptor on microglia) appears to control how well immune cells clean up toxic proteins in the brain. Drug developers can now create antibodies or small molecules that activate TREM2, essentially “training” the brain’s immune cells to do their job better. The Salk Institute’s Neuroimmunology Initiative is examining these interactions in detail, showing how damage-repair cycles in the immune system drive the buildup of amyloid and tau—the hallmark proteins of Alzheimer’s disease.
Five Drug Candidates in Active Clinical Trials Targeting Brain Immunity
Three drugs have advanced to Phase II clinical trials specifically for Alzheimer’s disease: AL002 (a TREM2-activating antibody), canakinumab (a monoclonal antibody that blocks IL-1β), and pegipanermin, also called XPro1595 (a selective TNF-α inhibitor). Each targets a different part of the immune cascade, reflecting how researchers now see neuroinflammation not as a single problem but as a complex system where multiple intervention points are possible. Canakinumab, for instance, was originally developed for rheumatoid arthritis—an autoimmune disease. The fact that it’s now being tested for Alzheimer’s reflects a growing recognition that autoimmune and neurodegenerative processes share common inflammatory pathways.
Beyond Alzheimer’s, masitinib—a selective tyrosine kinase inhibitor that dampens immune signaling—showed improvement in disease progression when tested in Phase 2 trials for ALS (amyotrophic lateral sclerosis), a devastating neurodegenerative condition. Metformin, an older drug typically used for diabetes, is currently being studied in multiple clinical trials for neurodegenerative diseases, particularly multiple sclerosis, because emerging research suggests it calms microglial activation. These repurposed and new drugs represent a fundamental shift: instead of designing drugs for single neurons or a specific protein, developers are now targeting the immune dialogue happening between microglia and neurons. The challenge, as detailed below, is that many of these immune-modifying molecules struggle to cross the blood-brain barrier, the protective membrane that prevents most drugs from reaching brain tissue.
From Cryo-EM Images to Clinical Drugs: The Anti-NMDAR Encephalitis Example
The February 2026 discovery of a new drug target for anti-NMDAR encephalitis illustrates how modern immunology research translates into actionable drug development. Anti-NMDAR encephalitis, known colloquially as “brain on fire,” is a rare autoimmune disease where the immune system mistakenly attacks NMDA receptors—crucial proteins for learning and memory. For years, treating the disease meant suppressing the entire immune system with steroids or immunosuppressants, leaving patients vulnerable to infection and other complications. Using cryo-EM (a technique that freezes proteins in place and images them at near-atomic resolution), researchers crystallized the exact shape of an antibody stuck to an NMDA receptor and saw precisely what was happening at the molecular level.
This visualization allowed researchers to design drugs that could specifically target that antibody or stabilize the receptor against antibody attack, rather than blanketing the immune system. This approach—moving from “suppress everything” to “target the specific misdirected immune response”—is now being applied to other autoimmune-linked brain conditions. It also highlights an important limitation: anti-NMDAR encephalitis is rare, so a drug targeting it may take years to get to market despite the scientific elegance of the approach. Rarer diseases can be economically challenging for pharmaceutical companies, which is why academic centers and nonprofit research initiatives like the Salk Institute are essential partners in this work.
Autoimmune Diseases and Neurodegeneration: A Surprising Connection Worth Treating
Recent research has uncovered that people with certain autoimmune disorders—like lupus, rheumatoid arthritis, and inflammatory bowel disease—have elevated risk of developing Alzheimer’s disease and other neurodegenerative conditions later in life. This connection suggests that chronic immune dysregulation, even if primarily attacking joints or the gut, leaves the brain vulnerable to degeneration. The implication is profound: treating autoimmune disease aggressively may prevent neurodegeneration, and conversely, drugs developed for autoimmune disease may have unexpected benefits for neurodegenerative disease. This cross-pollination of drug development is already happening, as with canakinumab moving from rheumatoid arthritis trials to Alzheimer’s trials.
Additionally, researchers are finding that anti-inflammatory approaches can treat conditions previously thought to be purely neurochemical. Early clinical trials of anti-inflammatory drugs for depression show promise by calming the immune system rather than targeting serotonin or other brain chemicals—a fundamental departure from conventional antidepressants. For people with treatment-resistant depression or depression comorbid with neurodegenerative disease, immune-targeting drugs might work where conventional antidepressants fail. However, this approach is still in early stages, and it’s not yet clear whether anti-inflammatory treatment will benefit all patients or only a subset with elevated inflammatory markers. Blood tests identifying “neuroinflammatory depression” may eventually become routine, but today, most people with depression are not screened for immune activation.
The Blood-Brain Barrier: The Biggest Hurdle in Brain Immune Drug Development
Despite the promise of immune-targeting drugs, a formidable obstacle remains: the blood-brain barrier (BBB), the highly selective membrane that controls what substances can pass from the bloodstream into brain tissue. Most anti-inflammatory molecules and antibodies are large or hydrophobic compounds that the BBB actively rejects. This means a drug that successfully dampens inflammation in joints or the bloodstream may not reach therapeutic concentrations in the brain where it’s needed most. Researchers have documented this problem extensively; many promising anti-inflammatory agents cannot effectively cross the BBB to reach pathological sites in the brain. Several strategies are being pursued to overcome this barrier.
Some researchers are engineering smaller antibodies or using nanoparticles as drug delivery vehicles to sneak past the BBB. Others are developing drugs designed to be small enough and lipophilic enough to cross passively. A third approach involves temporarily weakening the BBB using ultrasound or pharmaceutical agents, though this carries risks of unwanted molecules also entering the brain. Until the BBB challenge is solved reliably, even drugs that show promise in lab studies may fail when tested in patients. This is why some drugs progress through Phase II trials successfully but stall in Phase III when their real-world effectiveness disappoints—the drug reached the brain, but not in sufficient quantity.
uPAR CAR T Cells and Engineered Immune Therapy for Glioblastoma
In a different approach to brain immune therapy, researchers working with Canada’s National Research Council developed a uPAR Chimeric CAR T cell candidate designed to reprogram immune cells to attack glioblastoma, one of the most deadly brain cancers. CAR T cell therapy involves removing immune cells from a patient, engineering them to recognize and attack cancer cells, and returning them to the body. In preclinical research, this uPAR-targeting CAR T cell candidate eliminated deadly glioblastoma tumors entirely in laboratory models.
The approach represents a shift from anti-inflammatory therapy (damping down immune activity) to pro-immune therapy (amplifying immune attack on a specific brain target). This dual strategy—sometimes suppressing immune overactivity in neurodegeneration, sometimes amplifying immune attack on brain tumors—shows that brain immune discoveries are enabling multiple types of drugs, not just a single therapeutic class. The challenge with CAR T therapy is that it requires individual customization for each patient and is logistically complex, making it expensive and not suitable for common diseases. However, for severe, rapidly fatal conditions like glioblastoma, the cost and complexity may be justified if survival improves dramatically.
The Future Landscape of Brain Immune-Targeted Drugs
Over the next five years, expect to see results from multiple Phase II and Phase III trials of brain-immune drugs. If AL002, canakinumab, or pegipanermin demonstrate meaningful slowing of cognitive decline in Alzheimer’s disease, they could reach patients as early as 2027-2028. Simultaneously, the field is expanding to consider immune targets in Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and post-stroke cognitive decline.
The Salk Institute and similar research centers are mapping out dozens of additional immune pathways that could be drugged, suggesting a pipeline of candidates for the next decade. One encouraging sign: the field is learning how to stratify patients by immune status, meaning future medications will likely come with a biomarker—a blood or CSF test showing elevated IL-1β or low TREM2 activity—that predicts who will respond. This personalized approach could make brain immune drugs more effective than broad-spectrum therapies, because patients selected for immune-driven disease would logically respond better to immune-targeting treatments. The transition from one-size-fits-all dementia drugs to immune-based precision medicine represents the next chapter in neurology.
Conclusion
Brain immune discoveries are moving from bench research into clinical practice faster than many expected. Multiple drugs targeting microglial activation, inflammatory cytokines, and autoimmune responses are in Phase II and Phase III trials, with the first results emerging by mid-2027. These medications represent a fundamental rethinking of brain disease—from seeing the immune system as a problem to be suppressed to viewing it as a system to be fine-tuned and leveraged for neuroprotection.
The journey from discovery to patient access will not be straight, and the blood-brain barrier remains an engineering challenge. But the combination of new immunological insights, advanced tools like cryo-EM, and pharmaceutical commitment to brain immune targets suggests that people diagnosed with Alzheimer’s disease, ALS, neuroinflammatory depression, and other conditions could have meaningful new treatment options within the next few years. Staying informed about clinical trial enrollment and discussing immune-based therapies with a neurologist will become increasingly important for people navigating brain health challenges.
